Complement Inhibition
Control over this interaction inhibits the complement cascade andprevents cell membrane damage, cell death, and organ rejection.
Pharmaceutical industry and biotech companies interested in early stagedevelopments with a potential in a wide range of application.
Compounds modulating CD59 mediated complement activity,compositions including these compounds, and methods of makingand using the compounds are available for licensing. Thesecompounds responsible for complement inhibition react at thebinding site for CD59-C9 interactions. Compounds can be derivedusing this basic amino acid sequence described andcorresponding three dimensional structure of the protein using anyof several techniques known to those skilled in the art, includingrational drug design.Those compounds imitating the structure and/or function of the peptide region bind to the active portions of human C9, as well as modified peptides. The compounds can be administered locally or systemically in any amount effective to either inhibit complement or block the inhibition of complement, in a patient in need of treatment. This discovery describes the interactions of C5b-9 complex with CD59 that shut down the complement system including the mechanism andregion of binding.Filed in US, PCT, EPC, and other foreign countries. Technology co-owned with the Oklahoma Medical Research Foundation.
美国
